Cerveau Technologies Inc.
60 State Street
Suite 700
Boston
Massachusetts
02109
United States
Tel: 617-610-5828
Website: http://cerveautechnologies.com
About Cerveau Technologies Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.LEADERSHIP:
President: Rick Hiatt
35 articles about Cerveau Technologies Inc.
-
Cerveau Technologies and Enigma Biomedical Group Sign Research Agreement with Centre for Addiction and Mental Health (CAMH), Toronto
11/20/2017
These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography scans for assessing the status and progression of neurofibrillary tangles in the brain.
-
Cerveau Technologies Signs Research Agreement With Houston Methodist
11/8/2017
Cerveau Technologies today announced an agreement with Houston Methodist Hospital to support multiple projects over the next several years.
-
Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau's Achievement of a Major Milestone in China Strategy
11/3/2017
Sinotau Pharmaceuticals has announced today an agreement with HTA CO. LTD for launching a new β-amyloid imaging agent for Alzheimer’s disease in China.
-
Cerveau Technologies Announces a Partnership With Landmark Alzheimer's Disease DIAN-TU Trial
10/31/2017
The trial will include Cerveau's MK-6240, an investigational imaging biomarker targeting disease progression.
-
Navidea Signs Letter of Intent to Sublicense NAV4694 Worldwide Development Rights
10/30/2017
Cerveau, and/or their fully controlled subsidiary, will act as a designated party for the rights resulting from the relationship between Navidea and Beijing Sinotau Medical Research Co., Ltd. (Sinotau), a subsidiary of Sinotau Pharmaceutical Group.
-
Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging Agent
10/23/2017
The relationship is focused on the use of [F-18]MK-6240 as a biomarker in clinical trials of drugs being developed for the treatment of Alzheimer’s disease.
-
Cerveau Technologies Signs Research Agreement With Columbia University Medical Center
10/20/2017
Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years.
-
Cerveau Technologies Signs Collaboration Agreement With Janssen For Novel Tau Imaging Agent
10/17/2017
Cerveau Technologies today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240.
-
Cerveau Technologies Announces Collaboration With Banner Health
9/20/2017
-
Cerveau Technologies Signs Collaboration Agreement With H. Lundbeck A/S For Novel Tau Imaging Agent
9/15/2017
-
Imanova Secures License From Cerveau Technologies To Manufacture Investigational Tau Ligand, [18F]MK-6240
7/5/2017
-
Imanova Secures License From Cerveau Technologies To Manufacture Investigational Tau Ligand, [18F]MK-6240
6/30/2017
-
Cerveau Technologies Announces Collaboration With NYU Langone Medical Center
6/26/2017
-
Cerveau Technologies Announces FDA Acceptance Of Investigational New Drug (IND) For Tau Imaging Agent MK-6240
6/16/2017
-
Cerveau Technologies Collaborates With Singapore’s Clinical Imaging Research Centre
5/25/2017